Glaxosmithkline has a share of around 5% of the world’s pharmaceutical market, aiming to tackle 3 of the ‘priority’ diseases identified by the World Health Organisation. The company employs around 96,500 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries.
With growth being so much better at Bristol Myers Squibb over last 11mths(50%+), that would mean if we play catch up ( Deutsche Bank says unlikely after Q3 sales dropped 61% ) we should be valued around +2000p. After all the bribery scandals and the patent expiration of Advair/Seretide, for which AstraZeneca's Symbicort is an alternative treatment. could we get back to 2000p with this new HIV blockbuster drug and also a possible aquisition. I found the idea of selling Lucozade a little bizarre as fundamentals prove more people are drinking sports drinks in last 10years than ever before. Swiss rivals Roche and Novartis, by contrast, both saw continued growth in their Chinese drug sales in the third quarter, where GSK's had a large drop.
25 Nov '13
I did say 'competitors' in the sentence...lol against AZN, JNJ and GSK! Wakey wakey! Try thinkingg thinks thru before u put fingers to keybaord! Lol
25 Nov '13
Well, if you will mix up two different stock exchanges in the same sentence.... ! LOL BMY is indeed the New York Stock Exchange ticker for Bristol Myers Sqibb (commonly known as BMS) but on the London Stock Exchange BMY is the ticker for the somewhat smaller Bloomsbury Publishing!
24 Nov '13
#Valuation & Growth prospects
http://money.cnn.com/quote/quote.html?symb=GSK Accumulate GSK, don't buy in one big swoop, as there are future hurdles with the economy when the trees will be shaken and you might be able to catch some cheaper later on... DYOR.
24 Nov '13
#Hope your ready!
http://www.seekingalpha.com/article/1753962?source=promotion_full_splash_iphone **************** Share performance GlaxoSmithKline (GSK) has returned 43% over the last five years and is the worst performing drug company in the peer group. Bristol-Myers Squibb (BMY) gained 182%, Sanofi (SNY) 82%, Merck & Co. (MRK) 72%, Pfizer (PFE) 83% and Novartis (NVS) 59%. GSK's performance is mediocre and some might say problematic. But problems often are an opportunity in disguise: GSK's strong vaccine pipeline and high cash flow yields make this company an interesting Buy candidate for investors.
24 Nov '13
#Warren Buffett cuts his holding
The Mesiah of stockholding has cut his holding in GSK by 77% & a nominal sale of Sanofi ( SNY ). Though he sold JNJ stake back in November 2012 when $65, now $95... GSK is getting overpriced on a P/E level of 21.3, to AZN of forward P/E of 10. I hold GSK, AZN, NVS, JNJ and have reduced my holding in NVS.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.